115 related articles for article (PubMed ID: 20378382)
1. Presence and diagnostic performances of IgA class antibodies to mutated citrullinated vimentin in rheumatoid arthritis.
Sghiri R; Khalifa O; Bouajina E; Ben Haj Slama F; Baccouche K; Ben Fredj H; Gaha R; Boukadida J
Joint Bone Spine; 2010 May; 77(3):279-80. PubMed ID: 20378382
[No Abstract] [Full Text] [Related]
2. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
[TBL] [Abstract][Full Text] [Related]
3. Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.
Rodríguez-Mahou M; López-Longo FJ; Sánchez-Ramón S; Estecha A; García-Segovia A; Rodríguez-Molina JJ; Carreño L; Fernández-Cruz E
Arthritis Rheum; 2006 Aug; 55(4):657-61. PubMed ID: 16874789
[No Abstract] [Full Text] [Related]
4. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis.
Al-Jarallah K; Shehab D; Al-Attiyah R; Al-Azmi W; Al-Fadli A; Zafar Haider M; Panaccione R; Ghosh S
Inflamm Bowel Dis; 2012 Sep; 18(9):1655-62. PubMed ID: 22114016
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
Zhu T; Feng L
Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
[TBL] [Abstract][Full Text] [Related]
9. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis.
Poulsom H; Charles PJ
Clin Rev Allergy Immunol; 2008 Feb; 34(1):4-10. PubMed ID: 18270850
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
13. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis.
Lindenberg L; Spengler L; Bang H; Dorner T; Maslyanskiy AL; Lapin SV; Ilivanova EI; Martinez-Gamboa L; Bastian H; Wittenborn E; Egerer K; Burmester GR; Feist E
Arthritis Res Ther; 2015 Aug; 17(1):206. PubMed ID: 26268352
[TBL] [Abstract][Full Text] [Related]
14. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
[TBL] [Abstract][Full Text] [Related]
15. [Significance and diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody and anti-mutated citrullinated vimentin antibodies in patients with serum negative rheumatoid arthritis].
Qu SJ; Ye H; Jia RL; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):933-936. PubMed ID: 27987492
[TBL] [Abstract][Full Text] [Related]
16. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
[TBL] [Abstract][Full Text] [Related]
17. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations and anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: comment on the editorial by Levesque et al.
Firestein GS
Arthritis Rheum; 2010 Jan; 62(1):303-4. PubMed ID: 20039399
[No Abstract] [Full Text] [Related]
19. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
20. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
